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Mechanical biofilm 
disruption causes microbial 
and immunological shifts 
in periodontitis patients
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J. L. Brown 1, G. Ramage 1, A. Mira 2,4 & S. Culshaw 1*
Periodontitis is characterized by subgingival biofilm dysbiosis, inflammation and tissue destruction. 
Current treatment involves mechanical biofilm disruption known as non-surgical periodontal therapy 
(NSPT). This study sought to characterise the impact of treatment on microbial diversity and overall 
community, and the parallel impact on host inflammation in the oral cavity. Fourty-two periodontitis 
patients were included in this study, with periodontal clinical parameters, subgingival plaque and 
saliva samples collected at baseline and 90 days after treatment. Salivary cytokines were quantified, 
and subgingival plaque was analysed using 16S rRNA sequencing. After treatment, there were marked 
health-associated alterations in microbial composition and diversity, including differential abundance 
of 42 genera and 61 species. These changes were accompanied by substantial clinical improvement 
(pockets ≥ 5 mm, 27.50% to 9.00%, p < 0.001) and a decrease in salivary IL-1β (p < 0.001)—a putative 
marker of periodontal inflammation. Despite significant reductions in disease associated anaerobes, 
several genera (Fusobacterium, Prevotella, Tanenerella, Treponema) remained present and formed 
a distinct subnetwork associated with residual disease. Collectively, this study shows that current 
periodontal treatment results in partial restoration of a healthy microbial ecosystem, but features 
of biofilm dysbiosis and host inflammation remain in some patients, which were surprisingly 
independent of clinical response.
Periodontitis (PD) is a highly prevalent, biofilm-mediated chronic oral inflammatory condition affecting 50% 
of the population, with 10% suffering from severe  disease1,2. PD arises via the formation of dysbiotic subgin-
gival plaque biofilms, which perpetuate an aggravated immune response within the gingival  tissue3. In turn, 
this leads to a continuous cycle of host-bacterial interplay, whereby inflammation facilitates greater dysbiosis 
of the microbiome, and vice-versa4. If left untreated, this immune response leads to irreversible damage to the 
periodontal ligament and alveolar bone, ultimately resulting in tooth loss in susceptible individuals. Emerging 
evidence suggests that the consequences of PD may extend beyond the oral cavity, with previous work suggest-
ing an association between periodontitis and risk of  diabetes5,6, rheumatoid  arthritis7–9,  atherosclerosis10,11, 
 hypertension12,13 and Alzheimer’s  disease14. Given the nutritional and psychosocial consequences of tooth loss 
and the links between PD and systemic disease, restoring periodontal health (PH) is essential to both oral and 
general health. Current treatments are resource intensive, time consuming and often only partially successful. 
Therefore, there is a need to understand the microbial and host immune response to further optimise treatment 
outcomes.
Several studies have consistently documented a unique bacterial signature of the subgingival plaque in PD, 
with Socransky’s seminal findings of distinct complexes—each designated a colour—desbribing related groups 
of bacteria based on their association with health and disease (red, orange, green, purple, blue, yellow)15. Of note, 
the ‘red complex’ consisting of Porphyromonas gingivalis, Tannerella forsythia and Treponema denticola were 
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found to strongly relate to PD severity. More recently, advances in molecular approaches have revealed that the 
diversity of the subgingival plaque is higher than previously  assumed16–20. Whilst the ‘red complex’ relationship 
with disease  remains21, large-scale analyses have revealed dysbiosis of the entire plaque community, associated 
with increased microbial diversity and anaerobic  bacteria16,17. In line with these findings, a recent systematic 
review documented several new species associated with PD such as Filifactor alocis, Fretibacterium fastidiosum 
and Treponema vincentii22.
Chronic inflammation in response to dysbiotic subgingival plaque biofilms is a consistent feature of PD and 
escape of locally generated inflammatory mediators into the circulation has been proposed as a putative link 
between oral and systemic  health23. Pro-inflammatory cytokines in saliva have been implicated as potential 
biomarkers for PD, with independent cross-sectional studies showing higher levels of several cytokines in PD 
compared with  health24,25. Yet, this does not appear to be consistent across independent studies and patient 
cohorts. For example, Ebersole et al., found that salivary Interleukin-1β and Interleukin-6 were elevated in 101 
PD patients compared with 65 healthy  controls24. In contrast, Teles et al., found no significant differences when 
assessing both cytokines in the saliva of 74 PD patients and 44 healthy  controls26. Hence, characterising how 
cytokines respond to improvements in clinical status may provide a critical insight into their role in PD.
Given the previous identification of host and microbial markers associated with PD, we sought to evaluate 
how these markers reflect disease severity and change following treatment and improvements in clinical status. 
Non-surgical periodontal therapy (NSPT) represents the first line of treatment for the majority of PD patients 
and involves physical debridement of biofilms from beneath the gum-line using hand or ultrasonic scaling instru-
ments, inducing widespread—although not total—clinical  improvement27, 28. To prevent disease recurrence and 
potential systemic complications, it is crucial to understand whether physical biofilm disruption is sufficient to 
reduce local inflammation and microbial dysbiosis. Salivary cytokines and microbiome have been well charac-
terised in cross sectional studies comparing health and  disease16,17,24,26; however, there is limited understanding 
of changes in response to treatment. In this study, we aimed to investigate the subgingival plaque microbiome 
and salivary inflammatory cytokines—in relation to baseline disease severity, and longitudinally following NSPT.
Methodology
Study population, treatment and clinical examination. This longitudinal study was conducted in 
accordance with the Declaration of Helsinki (2013), with ethical approval (London-Stanmore Research Ethics 
Committee, Reference: 14/LO/2064). Eligible patients were recruited from referrals to Glasgow Dental Hospital. 
Periodontitis was defined as probing pocket depths ≥ 5 mm on 2 or more teeth at non-adjacent sites excluding 
third  molars29. Additional inclusion criteria included written informed consent, and male or female ≥ 18 years of 
age. Exclusion criteria included patients with diabetes, rheumatoid arthritis, known or suspected risk of tubercu-
losis, hepatitis B or HIV infections, or history of bleeding diathesis. In total, 45 patients were recruited and pro-
vided written consent to take part in the study. Three patients were subsequently excluded due to a new diagnosis 
of a systemic disease during the trial period. Therefore, 42 patients were included for analysis.
NSPT was delivered by a single experienced dental hygienist, who was calibrated with experienced periodon-
tists. Patients returned for varying numbers of treatment visits (between 1–6) depending on disease severity and 
preference for treatment scheduling. Periodontal parameters were assessed before any treatment visits (baseline) 
and 90-days following the last treatment visit (day 90) (Fig. 1A). Periodontal parameters were assessed at six sites 
per tooth, including full-mouth plaque  scores30 and full-mouth bleeding  scores31 (Fig. 1B). Periodontal pocket 
depths (PPD), location of the gingival margin (LGM) and clinical attachment level (CAL) were recorded to the 
nearest millimetre per site and divided by the total number of sites to give average full-mouth scores. The peri-
odontal inflamed surface area (PISA) was calculated as described  previously32.
Sample collection and processing. Subgingival plaque and saliva were collected at baseline and day 
90. At baseline, subgingival plaque was collected from the deepest pocket in each quadrant using a curette and 
placed into an Eppendorf tube containing 500uL sterile phosphate buffered saline (Sigma Aldrich, Gillingham, 
UK). Bacterial cells were harvested via centrifugation (13,500 RPM for 10-min) and supernatant was discarded. 
One site was selected from each patient for sequencing, and samples from the same site were sequenced before 
and after treatment to ensure accurate longitudinal analysis. Samples collected from the upper right quadrant 
were preferentially selected (n = 35), unless unable to sample the same site at day 90. In this case, pre- and 
post-treatment samples from a different quadrant were selected; upper left (n = 1), lower right (n = 3), lower left 
(n = 3). Saliva was collected using the passive drool method and was clarified via centrifugation (13,000 RPM for 
5-min) as described  previously33. All samples were transferred to adjacent laboratories and processed immedi-
ately. Samples were stored at -80 °C until analysis.
Analysis of salivary cytokines. Concentrations of salivary tumour necrosis factor α (TNFα), interleu-
kin-6 (IL-6) and interleukin-1β (IL-1β) were determined using enzyme-linked immunosorbent assay (ELISA) 
kits (Thermofisher, Loughborough, UK). Salivary interleukin-8 (IL-8) was quantified using DuoSet ELISA kit 
(Biotechne—R&D Systems, Abingdon, UK). Salivary interleukin-17A (IL-17A) was quantified using high-sen-
sitivity ProQuantum immunoassays, performed using a StepOne plus real-time PCR analyser (Thermofisher, 
Loughborough, UK). Samples were diluted 1:2 for IL-1β, TNFα and IL-6 assays, 1:3 for IL-8 assays and 1:5 for IL-
17A assays, as per manufacturers instructions. One patient had limited sample volume and was not included in 
any salivary analysis (n = 41 for salivary cytokines). The limit of detection (LOD) for cytokines was IL-6: 0.04 pg/
mL, IL-1β: 1.35 pg/mL, IL-8: 6.78 pg/mL, TNFα: 0.14 pg/mL and IL-17A: 2.75 pg/mL. IL-6, IL-1β and IL-8 were 
detected in all samples. TNFα was < LOD in 3 samples (1 at baseline, 2 at day 90) and IL-17A was < LOD in 12 
samples (10 at baseline, 2 at day 90). For statistical analysis, samples < LOD were assigned LOD/2.
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Bacterial 16S rRNA sequencing. DNA was extracted from subgingival samples (baseline and day 90) 
using the MagNA Pure LC DNA isolation kit (Roche Diagnostics, Mannheim, Germany) with the addition of 
a chemical lysis step with an enzymatic cocktail containing lysozyme, mutanolysin and lysostaphin, follow-
ing Rosier et al.  202034. DNA concentrations were measured using a QubitTM 3 Fluorometer (Thermofisher, 
Waltham, Massachusetts, USA), and an Illumina amplicon library was prepared following the 16S rRNA gene 
Metagenomic Sequencing library preparation Illumina protocol (Part #15,044,223 Rev. A). The primer sequences 
used in this protocol were; Illumina_16S_341F (TCG TCG GCA GCG TCA GAT GTG TAT AAG AGA CAG CCT 
ACGGGNGGC WGC AG) and Illumina_16S_805R (GTC TCG TGG GCT CGG AGA TGT GTA TAA GAG ACA 
GGA CTACHVGGG TAT CTA ATC C) which target the 16S V3 and V4 region. Following amplification, DNA 
was sequenced with an Illumina MiSeq Sequencer according to manufacturer’s instructions using the 2 × 300 
base paired-ends protocol. For taxonomic classification, an amplicon sequence variant (ASV) table was obtained 
using the DADA2 pipeline in  R35. Taxonomy was assigned by comparison to the SILVA  database36, where the 
naive Bayesian classifier was used to assign sequences at the genus- and species-level.
Data analysis. Data was initially collected into SPSS (v26, IBM). Following collection, longitudinal analysis 
of clinical characteristics and salivary cytokines was performed using GraphPad PRISM (v8) using Wilcoxon 
signed rank tests. Correlation analysis was conducted using Spearman-rho (non-parametric) or Pearson’s (para-
metric) depending on data distribution, which was determined by visual inspection of histograms.
For analysis of the subgingival plaque microbiome, R programming language (v3.4 +) was used for statistical 
 computing37. Alpha-diversity indexes (Shannon, ACE, Chao1) were calculated at species-level rarefying to 9000 
reads using the Vegan library in  R38, and longitudinal differences were assessed using paired t-tests in GraphPad 
PRISM (v.8).
Relative abundances were calculated using the total sum scaling (TSS) method. Only genera and species with 
a minimal signal of detection were included in microbiome statistical analysis. Specifically, a species or genus 
was included if it was present in 50% of the samples from at least one of the two groups (relevant for Wilcoxon 
tests) or from the given group under study (relevant for association networks and Spearman’s correlations) 
with an abundance superior to five times the smallest percentage above zero. For univariate analyses, Wilcoxon 
signed rank tests (i.e., wilcox.test function of stats library of R) were performed to test the differences in genera 
and species between baseline and day 90, corrected for multiple comparisons using the Benjamini–Hochberg 
false discovery rate (FDR) of 5%39. Thus, only adjusted p-values are reported for taxonomic comparisons. To 
compare the abundance of known health and disease-associated organisms, species were grouped according the 
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Figure 1.  Outlining study protocol (A) and collection of periodontal clinical measurements (B). Six sites 
around each tooth were measured for plaque index, BOP, PPD and CAL. CEJ; Cementoenamel junction, 
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colour complexes outlined by Socransky et al15. The grouping represents the sum of relevant species, outlined 
in Supplementary Table 2.
For association networks, pairwise associations were computed between genera and species based on a mul-
tivariant approach described by González et al.40, which was implemented in the ’mixOmics’ R  package41. In 
short, association between genera and species are obtained based on their projection onto a correlation circle 
plot derived from a principal component analysis. In the association networks, only negative associations below 
-0.4 and positive associations above 0.4 between genera are shown. The network graphs were obtained with the 
R ‘ggraph’  package42. To complement the association networks, correlations between genera and species were 
determined with Spearman’s rho, along with associated p-value using the cor.test function.
For multivariant analysis, an Adonis test (Permutational Multivariate Analysis of Variance Using Distance 
Matrices), provided by the Vegan library of  R38, was used to compare the overall composition between groups. 
To visualize groups and their differences in a two-dimensional map, we computed constrained principal compo-
nents via constrained correspondence analysis (CCA) which is also part of Vegan  library38. Principal coordinate 
analysis (PCoA) was conducted using  MicrobiomeAnalyst43, with Bray–Curtis similarity calculated using PAST 
software (v4.01)44. All graphs were assembled using GraphPad PRISM (v8) or  R37.
Results
Study population and clinical parameters. Patients with periodontitis who required specialist peri-
odontal treatment were recruited (Fig. 1A). The average age of patients included in the analysis was 50 years old, 
with 12 males and 30 females (Supplementary Table 1). Following treatment, there was a marked improvement 
in all periodontal clinical parameters (p < 0.001 for all, Table 1). Compared with full-mouth parameters (average 
of all teeth), there was higher disease severity at baseline and greater clinical improvement following treatment 
in sites from which subgingival plaque samples were collected (PPD and CAL, both p < 0.001, Table 1).
The microbiome following periodontal treatment. Sequencing of subgingival plaque samples 
yielded 4745 ASVs across 84 samples, with an average of 90,830 reads per sample (ranging from 35,372 to 
343,259 reads). After removing singletons, these ASVs were classified into 206 genera and 379 species. Rarefac-
tion curves suggested a reliable estimate of taxonomic diversity was feasible rarefying to 9,000 reads per sample 
(Fig. 2A). Following treatment, there was a marked reduction in subgingival plaque taxonomic diversity, inde-
pendent of method of evaluation (p < 0.001 for all, Fig. 2B).
Along with shifts in microbial diversity, treatment resulted in clear alterations to the microbiota composi-
tion, identified using CCA analysis at genus—(Fig. 3A) and species-level (Fig. 3B). Evaluation of genera and 
species which differed significantly revealed changes in 42 genera and 61 species comparing baseline and day 90 
samples (Supplementary Fig. 1). Of the 42 genera, 34 decreased whilst 8 increased in abundance; at species level 
46 species decreased and 15 species increased in abundance following treatment (Supplementary dataset 1). To 
identify genera and species contributing most to the compositional alterations, a further abundance filter (average 
abundance > 0.15% at either timepoint) was applied, and demonstrated differential abundance of 31 genera and 44 
species. Of the 31 genera, 25 decreased whilst 6 increased in abundance (Fig. 3C). A similar trend was observed 
at species-level, with 32 species decreasing and 12 species increasing in abundance following treatment (Fig. 3D).
Overall there was a clear trend whereby the abundance of strict anaerobic species decreased following NSPT, 
and facultative anaerobic or aerobic bacteria increased. Interestingly at species-level the largest fold-increase was 
found for Porphyromonas pasteri (p[adjusted] = 0.02) belonging to a conventionally disease-associated genus, 
though it remained at relatively low abundance (0.6% of total, Supplementary Fig. 1).
Changes in health and disease-associated organisms. Historically, Socransky et al.15 identified dis-
tinct complexes and assigned each a colour (red, orange, green, purple, blue and yellow), depending on their 
strength of association with disease. Red and orange complexes contain groups of disease-associated organ-
Table 1.  Comparison of periodontal parameters at baseline and day 90 (n = 42). Data represent full-mouth 
and the site from which subgingival plaque was harvested. Data are displayed as medians (Q1, Q3). FMPS; full-
mouth plaque score, FMBS; full-mouth bleeding score, PPD; probing pocket depth, CAL; clinical attachment 
level, PISA; periodontal inflamed surface area. § p-values refer to Wilcoxon signed rank test.
Variable Baseline (n = 42) Day 90 (n = 42) p-value§
Full-mouth
FMPS (%) 71.00 (46.75, 76.50) 12.0 (8.75, 29.25)  < 0.001
FMBS (%) 61.00 (32.75, 76.25) 8.00 (3.75, 15.25)  < 0.001
PPD (mm) 3.59 (3.08, 4.16) 2.78 (2.56, 3.02)  < 0.001
PPD ≥ 5 mm (%) 27.50 (18.75, 41.75) 9.00 (5.75, 12.25)  < 0.001
CAL (mm) 4.43 (3.73, 5.33) 3.72 (3.18, 4.31)  < 0.001
PISA  (mm2) 1224.60 (754.80, 1687.08) 138.85 (65.52, 293.88)  < 0.001
Sites from which plaque sample collected
PPD (mm) 7.00 (6.00, 8.00) 4.00 (4.00, 5.00)  < 0.001
CAL (mm) 8.00 (7.00, 9.00) 6.00 (5.00, 7.00)  < 0.001
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isms, whilst the green, purple, blue and yellow complexes contain species more associated with PH (Supplemen-
tary Table 2). Following treatment, there were significant reductions in the abundance of the red and orange 
complexes (p < 0.001 for both). No difference was observed in green and purple complexes, whilst significant 
increases were found in the blue (p < 0.01) and yellow (p < 0.001) complexes at day 90 (Fig. 4A). A recent review 
by Perez-Chaparro et al., identified a more complex community of disease associated  bacteria22, and there was 
a similar reduction in the abundance of these species following treatment when grouped together (p < 0.001, 
Fig. 4B). Significant decreases were found in the majority of individual species within this group (p < 0.05, Wil-
coxon signed rank tests), with the exception of Treponema medium and Mogibacterium timidum, which were 
present only at very low abundance.
Genera abundance and association networks. Along with compositional changes (Supplementary 
Fig. 2), analysis of bacterial association networks revealed a shift in the overall community structure. Network 
analysis was performed using correlation circle plots (Supplementary Fig. 3), and highlighted distinct clustering 
of individual genera and species at each timepoint. Most associations shown between genera (93.2% at baseline, 
90.0% at day 90) and species (88.3% at baseline, 90.3% at day 90) were supported by significant Spearman-Rho 
correlations (p(adjusted) < 0.05, Supplementary dataset 1).
At baseline there were two disease-associated clusters consisting of anaerobic genera (Fig. 5A). The first 
pre-treatment network consisted of Prevotella, Selenomonas, Dialister, Solobacterium, Olsenella and Atopobium, 
whilst Eikenella and Aggregatibacter showed negative associations with some of these genera (Fig. 5A, red lines). 
Within the second cluster, Filifactor and Fretibacterium were central players, both correlating positively with all 
three red-complex genera (i.e., Porphyromonas, Treponema, Tannerella). After treatment (Fig. 5B), a new disease-
associated network was observed consisting of Treponema, Prevotella, Parvimonas, Fusobacterium, Alloprevotella, 
Selenomonas, Dialister, and Catonella. Importantly, Rothia showed negative associations with Selenomonas, Fuso-
bacterium, and Prevotella of this cluster, whilst a positive correlation was found between Rothia and Actinomyces.
Similar results were observed at species-level, where Filifactor alocis, Fretibacterium fastidiusum and Freti-
bacterium feline were central in a closely associated network of anaerobic bacteria, forming strong connections 
to various PD-associated organisms at baseline (Fig. 5C). Following treatment (Fig. 5D), Rothia dentocariosa 
negatively associated with unclassified Selenomonas sp. and Lachnoanaerobaculum sp., whilst Corynebacterium 
Figure 2.  Alpha-diversity of subgingival plaque samples. Rarefaction curves for observed species at baseline 
(red line) and day-90 (blue line) (A). Comparing Shannon, ACE and Chao1 indexes before and after treatment 
at species-level rarefied to 9000 reads (B). Statistics are paired t-test, ***p < 0.001. n = 42. Bars represent mean 
with individual values shown.
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Figure 3.  Assessing longitudinal changes in the composition of sub-gingival plaque samples following 
treatment. Canonical Correspondence Analysis (CCA) comparing baseline (red) and day-90 (blue) samples 
at genus- and species-level (A and B respectively).  Log2 fold change of all significant genera (C) and species 
(D) with average abundance > 0.15% at either timepoint. Positive values (blue bars) indicate organisms which 
increased significantly following treatment, negative values (red bars) indicate organisms which decreased 
significantly following treatment. Wilcoxon signed rank test, corrected using Benjamini–Hochberg false 
discovery rate (5%). All plotted organisms p(adjusted) < 0.05. n = 42. NA indicates no classification was obtained 
at genus- or species-level.
7
Vol.:(0123456789)
Scientific Reports |         (2021) 11:9796  | https://doi.org/10.1038/s41598-021-89002-z
www.nature.com/scientificreports/
Figure 4.  Comparing the abundance of health and disease associated species in the subgingival plaque. 
Species detected by 16S rRNA sequencing were grouped in the Socransky (1998) red, orange, green, purple, 
blue and yellow complexes (A). Comparing the sum of ‘novel’ species associated with disease identified by 
Perez-Chaparro (2014) (B). Species included in figure B are; Treponema medium, Peptostreptococcus stomatis, 
Prevotella denticola, Mogibacterium timidum, Filifactor alocis, Selenomonas sputigena, Alloprevotella tannerae, 
Anaeroglobus geminatus, Fretibacterium fastidiosum, Porphyromonas endodontalis, Treponema vincentii, 
Treponema lecithinolyticum and Dialister pneumosintes. Tukey box plots of all individuals (N = 42) are shown. 
Wilcoxon signed rank test where ***p < 0.001, *p < 0.05, ns means no significant difference. P-values were 
adjusted using FDR (5%).
Figure 5.  Bacterial association networks. Association networks were constructed between abundant genera 
and species based on correlation circle plots derived from  principal component analysis at each timepoint. (A) 
Genus-level network at baseline, (B) genus-level network at day 90, (C) species-level network at baseline, (D) 
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matruchottii showed negative associations with Fusobacterium nulceatum and Parvimonas micra, two orange-
complex species.
Microbiome, disease severity and response to treatment. To investigate the relationship between 
the microbiota and clinical disease severity, Spearman-Rho correlations were performed between the pocket 
depth of sampled teeth, individual genera/species abundance and alpha-diversity indexes. No associations were 
observed between the site pocket depth and the abundance of any genera or species. However, when consider-
ing the disease severity of the entire tooth (average of the 6 sites), several positive and negative associations 
were noted. At baseline, there was a weak positive correlation between tooth pocket depth and alpha-diversity 
indexes, particularly the Shannon index (r = 0.403, p = 0.008), whilst no association was found with the abun-
dance of any individual genera or species. At day 90, there was no association with the Shannon index (Sup-
plementary Table 3). Instead, weak positive correlations were observed between tooth PPD and strict anaerobic 
genera (Treponema, Prevotella, Parvimonas, Alloprevotella, Dialister and unclassified Clostridiales Family XIII), 
whilst negative correlations were observed for facultative anaerobes (Corynebacterium, Granulicatella and King-
ella). Interestingly, all of the genera which positively correlated with tooth pocket depth were also key members 
of the remaining disease-associated network identified at day 90 (Fig. 5C). In contrast, Corynebacterium, which 
negatively correlated with pocket depth, showed negative associations with two of these genera (Dialister and 
Parvimonas).
To establish whether microbial profiles impacted treatment response, an exploratory analysis was conducted 
and patients were grouped depending on whether ‘pocket closure’ was achieved in the sampled sites (defined as 
the conversion of a site measuring ≥ 5 mm to a site measuring ≤ 4 mm)27,45. Sites < 5 mm were sampled in two 
patients at baseline, and these patients were excluded from this analysis (Supplementary dataset 1). Evaluating 
pocket closure rates within the remaining sites (n = 40), 21 sites achieved pocket closure at day 90, whilst 19 
sites did not. When comparing pocket depths at baseline between these two groups, no significant difference 
was observed indicating similar levels of starting disease severity (Fig. 6A). There were statistically significant 
reductions in pocket depth in both groups, albeit less pronounced in sites which did not achieve pocket closure 
(p < 0.001). To investigate the difference in the baseline microbiota of each group, a Bray–Curtis based principal 
coordinate analysis was performed (Fig. 6B). Despite differences in clinical outcomes, there was no significant 
difference in baseline microbial profiles of each group. Likewise, no difference was observed in Bray–Curtis 
similarity profiles (BL vs. D90), indicating similar microbial responses to NST (Fig. 6C). Comparing the relative 
abundance of species revealed no significant differences between groups at either timepoint (Fig. 6D), which was 
consistent for alpha-diversity indexes (data not shown). Additional exploratory analysis revealed no differences 
in baseline microbial profile or response among different demographic (sex, age) and behavioural subgroups 
(smoking status) within the current cohort (Supplementary Fig. 4).
Inflammatory response, disease severity and response to treatment. Given the key role of inflam-
mation in periodontal pathogenesis, we next sought to investigate whether clinical and microbial improvements 
were accompanied by alterations in the local inflammatory response. At baseline, salivary IL-1β showed a posi-
tive association with all clinical parameters, including the PISA (r = 0.534, p < 0.001), which reflects the inflam-
matory burden of PD (Fig. 7A). A weak positive association was observed between salivary IL-8 and full-mouth 
pocket depth, proportion of deep periodontal pockets and the PISA (r = 0.423, 0.424, 0.372 respectfully), whilst a 
weak negative association was observed between IL-17A and plaque index (r = − 0.375, p = 0.049). Salivary TNFα 
and IL-6 showed no significant association with any periodontal clinical parameter. Additionally, no significant 
positive or negative association between genera or species abundance and salivary cytokines was observed at 
either timepoint following adjustment for multiple comparisons (Supplementary Table 4).
Following treatment (Fig. 7B), there was a notable reduction in salivary IL-1β (p < 0.001), and, somewhat 
surprisingly, an increase in the level of salivary IL-17A, albeit a quantitatively small change (p < 0.001). No 
significant longitudinal changes were observed for TNFα, IL-6 or IL-8. To further evaluate the relationship 
between clinical disease and local inflammation, we assessed correlations in the change in each cytokine against 
the change in PISA (Fig. 7C). The change in salivary IL-1β showed a positive correlation with the change in the 
PISA, matching its association with disease severity at baseline and reductions following treatment. Despite the 
lack of change at day 90, salivary IL-8 also showed a similar relationship (r = 0.45, p = 0.003), whereby those with 
the greatest reduction in PISA tended to show a reduction in salivary IL-8 following treatment, whilst patients 
with less pronounced changes appeared to show similar or increased levels compared with baseline.
Discussion
Although previous studies have evaluated the microbiome following  NSPT46–48, to our knowledge, this is the first 
study to simultaneously investigate longitudinal alterations in the subgingival plaque microbiome, local inflam-
matory markers and periodontal clinical parameters in the same patient cohort. Furthermore, this study has 
one of the largest cohorts for studying alterations in the subgingival plaque microbiome. In our study, we show a 
clear decrease in disease associated organisms in the subgingival microbiota after NSPT, which was accompanied 
by alterations in salivary cytokines. Although patients all showed positive clinical changes, only 47% obtained a 
PISA commensurate with periodontal health (130.33mm2)49—which is comparable with a myriad of published 
studies. Thus, defining how patients respond to non-surgical periodontal treatment—encompassing clinical, 
microbial and inflammatory markers is critical to rationally test and implement much needed NSPT adjuncts 
and novel therapeutics.
Previous studies comparing PH and PD have shown higher microbial diversity in the subgingival plaque of 
PD patients, suggesting that increased pocket depths, nutrient availability and/or immune impairment allow 
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for growth of a more diverse biofilm  community16,50. In line with this theory, we observed consistent reductions 
in diversity following treatment, matching with reduced pocket depths and clinical inflammation. Along with 
shifts in taxonomic diversity, we observed differential abundance of 42 genera and 61 species following NSPT, 
representing large-scale alterations in the microbiota composition. The majority of organisms that decreased 
following treatment were strict anaerobes (e.g. Fusobacterium, Prevotella, Porphyromonas), with increases found 
typically in facultative anaerobes or aerobes (e.g. Kingella, Rothia, Actinomyces). This trend indicates that in addi-
tion to physical biofilm disruption, clinical improvement likely drives environmental shifts which contribute to 
biofilm composition, such as increased oxygen availability (from decreased pocket depths) and the reduction of 
inflammation-related nutrient  availability51,52.
Interestingly, we observed no significant microbiota differences between sites that did and did not achieve 
pocket closure, despite similar baseline disease severity. This study uniquely investigated the entire subgingival 
plaque microbiome factoring in pocket closure as a clinically relevant treatment outcome for patients receiving 
NSPT. We selected this outcome as the most clinically meaningful threshold which determines the need for 
further active  treatment27. Similar data has been reported previously in a smaller cohort when PPD, CAL and 
BoP were used as indicators of treatment  success47. An important observation to consider when interpreting 
the analysis from the current study is that even sites which did not achieve pocket closure did display sig-
nificant, albeit less pronounced, clinical improvement following treatment. Future studies incorporating true 
‘non-responders’ to NSPT would be useful to establish any causation between the baseline subgingival plaque 
microbiota and response to treatment.
Assessing longitudinal changes within the entire cohort, we observed a significant decrease in the levels 
of disease associated species following treatment, including Fretibacterium fastidiosum, Fretibacterium feline 
and Filifactor alocis. Filifactor alocis has been suggested as a biomarker for periodontitis and was proposed as 
Figure 6.  Investigating the subgingival plaque microbiome in relation to treatment response. (A) Comparing 
the pocket depth of sampled sites at baseline (BL) and day 90 (D90) depending on whether pocket closure 
was achieved (n = 21) or not achieved (n = 19) post-treatment. Dotted black line indicates 5 mm. Between 
group comparisons refer to unpaired t-tests (ns: non-significant, ***p < 0.001), within-group comparisons refer 
to paired t-tests (†p < 0.001), graphs display mean ± 95% confidence interval. (B) Species-level Bray–Curtis 
based PCoA analysis of each group at baseline, statistics are PERMANOVA with raw p-value displayed. (C) 
Comparing Bray–Curtis similarity with baseline between groups, statistics refer to Mann–Whitney test, ns: non-
significant. (D) Plotting the top 30 most abundant species at BL and D90 between groups, No; pocket closure 
not achieved, Yes; pocket closure achieved.
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a diagnostic marker  organism53,54. In addition, Fretibacterium spp., including F. fastidiosum, have been associ-
ated with PD in different independent studies. Interestingly, red complex genera (Porphyromonas, Treponema, 
Tannerella) correlated positively with Filifactor and Fretibacterium at baseline in our study, which led to the 
formation of a clearly disease-associated cluster. After treatment, these associations were lost and a newly formed 
disease-associated network was formed, including genera that are abundant in health but increase in PD (e.g., 
Fusobacterium and Prevotella)16, along with Treponema, Alloprevotella, Selenomonas, Parvimonas, Dialister and 
Catonella. Whether groups of disease-associated organisms may persist to drive future disease recurrence remains 
unclear, and requires a longer study period with microbiological monitoring.
Positive associations provide a useful indicator of key interactions within the subgingival plaque that drive 
dysbiosis; although investigating negative associations between organisms is an often-overlooked concept in 
PD. Such associations may elucidate interactions which help maintain the biofilm in a eubiotic state and could 
be a useful starting point for identifying potential probiotics. In our study at day 90, we observed negative 
associations between Rothia and several PD-associated genera (Selenomonas, Fusobacterium and Prevotella), 
and a positive correlation between Rothia and Actinomyces. Both Rothia and Actinoymces are confirmed nitrate 
reducing  genera55,56, and several strictly anaerobic PD-associated species have shown to be sensitive to oxidative 
stress and nitric  oxide57. Thus, the possible role of nitric oxide and other antimicrobial components produced 
by these genera in the inhibition of PD-associated organisms and maintenance of biofilm eubiosis warrants 
further investigation.
In previous smaller studies assessing the subgingival plaque microbiome following NSPT, ungrouped genera 
such as Dialister and Olsenella decreased post-treatment, whilst Rothia and Corynebacterium increased 47,48, 
commensurate with our results. However, a greater number of microbial alterations were observed in the current 
study. For example, Shi et al., demonstrated an increase in 4 genera and decrease in 8 genera across 12 patients 
following NSPT, whilst Chen et al., included 19 patients and observed large patient-to-patient variation in 
microbial response. In our study of 42 patients, we identified consistent shifts in 42 genera and 61 species. One 
reason for these findings may be that in previous  studies48, patients returned at varying timepoints (4–19 weeks) 
which may impact the stage of biofilm redevelopment and thus composition. In contrast, all patients returned at 
90 days following treatment in this study, which is a recommended clinical follow-up  period58. Taken together, a 
larger sample size and standardised follow-up period may help explain the greater number of microbial altera-
tions found in the current study following treatment.
Figure 7.  Levels of local inflammatory markers in saliva. (A) Correlating the levels of salivary inflammatory 
markers at baseline with clinical periodontal parameters, values represent Spearman-Rho correlation. P-values 
were corrected using FDR (5%) where *p(adjusted) < 0.05 and **p(adjusted) < 0.01. Confidence intervals are 
supplied in supplementary dataset 1 (B) Comparing changes in the levels of TNFα, IL-6, IL-8, IL-17A and IL-1β 
at baseline (BL) and day-90 (D90). Graphs are Tukey boxplots where horizontal line indicates the median and 
individual points indicate potential outliers. Statistics are Wilcoxon signed rank test, where ***p < 0.001. n = 41. 
(C) Pearson’s correlation between change in PISA and change in salivary cytokines, raw p-values are shown.
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From an inflammatory perspective, this study highlights a clear association between salivary IL-1β and peri-
odontal inflammation, supporting previous cross-sectional and longitudinal  studies25,59,60. However, this result 
was not observed for other pro-inflammatory markers (TNFα, IL-6, IL-8). In general, salivary levels of TNFα 
and IL-6 are  low61,62, and, similar to our findings, previous studies have failed to demonstrate a consistent rela-
tionship between salivary IL-8 and  PD63. Saliva is a harsh environment containing mucins, bacteria and various 
proteolytic enzymes. Therefore, it is possible that low values of TNFα and IL-6 merely represents their ability to 
survive in this setting, rather than lack of production within gingival tissue.
To our surprise, we observed a significant increase in the levels of salivary IL-17A after treatment. Primarily 
produced by Th17 cells, IL-17A plays an important role in the host defence against external pathogens at mucosal 
 sites64. Despite this function being co-aligned with the pathophysiology of PD (biofilm challenge in the peri-
odontal pocket), in reality, the relationship between IL-17A and PD remains complex and unclear, with evidence 
to suggest both protective and destructive  effects65. Previous cross-sectional studies assessing local production 
of IL-17A in the gingival crevicular fluid (GCF) and saliva have been largely incolclusive, with some studies 
reporting higher levels in  PD66,67, whilst others find higher levels in  PH68,69. Another study reported elevated 
levels in localised PD compared with generalised PD and PH, suggesting that IL-17A may peak in early gingival 
inflammation rather than established  periodontitis70. In relation to our study, day 90 samples are reflective of a 
post-treatment state of stability, rather than total periodontal health. Given the findings by Liukkonen et al., it is 
possible that treatment induces a shift back to an early inflammatory state, where IL-17A is a driving force. To 
further investigate this hypothesis, it would be beneficial for future studies to compare salivary IL-17A across a 
range of clinical states, including post-treatment PD, gingivitis and healthy patients.
Whilst the overall goal of this study was to identify longitudinal changes in clinical, microbial and immuno-
logical parameters post-treatment—certain limitations remain, and results should be interpreted in consideration 
of these factors. One such limitation is the lack of healthy control samples for a comparison with post treatment 
clinical health. Despite observing consistent shifts in known disease associated microbial and immunologi-
cal  markers15,22,61,62,71, future studies should investigate whether these resort back to a state comparable with 
periodontally healthy subjects. Another limitation is that patients were only followed-up at a single timepoint. 
Patients are evaluated three months following non-surgical treatment, and decisions made about future treat-
ment  plans72. Future studies could consider the impact of supportive treatment, repeated treatment, or adjunc-
tive treatments on the microbiome, and whether the microbiome post NSPT could be used to guide decision 
making. Evaluating the microbiome at earlier timepoints would provide a much-needed indication of the early 
microbial recolonization pattern following biofilm disruption. Longer follow up evaluation (6 months—1 year) 
would establish whether shifts are maintained, and which (if any) could be used to predict disease recurrence.
In conclusion, we present the first longitudinal study of NSPT to evaluate local inflammatory cytokines and 
microbiome sequencing in the same patient cohort. Our data highlight large-scale subgingival community shifts 
following NSPT, consistent with the reformation of an ecosystem more compatible with PH. However, a tightly 
clustered network of disease-associated genera remained at day 90, underlining the resilience of a microbial core 
that may be partly responsible for the chronicity of the disease. From an inflammatory perspective, our study 
confirms the relationship between salivary IL-1β and PD, showing a close association with periodontal inflam-
mation, and a proportional reduction following treatment. Collectively, this study shows that current treatment 
results in partial restoration of health but features of biofilm dysbiosis and inflammation remain. Means of 
modifying these parameters to improve clinical outcomes and reduce disease recurrence—that are not antibiotic 
dependent—are very much needed to improve periodontal treatment outcomes.
Data availability
A supplementary dataset containing figure source data accompanies this manuscript. All sequencing reads are 
deposited in the NCBI Sequencing Read Archive (SRA) under BioProject PRJNA725103. Any further data is 
available upon reasonable request from the corresponding author.
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